Florence Cymbalista

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 583 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Barbara Eichhorst, Tadeusz Robak, Emili Montserrat et al. · Annals of Oncology · 2020 · 548 citations

Hematological Malignancy, Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia +8

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W. Flinn, Peter Hillmen, Marco Montillo et al. · Blood · 2018 · 331 citations · Full text

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Jennifer R. Brown, Javid J. Moslehi, Susan O’Brien et al. · Haematologica · 2017 · 252 citations · Full text